Published in Vaccine on June 01, 1996
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog (2012) 1.50
Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl Environ Microbiol (2008) 1.19
Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis (2014) 0.91
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis (2006) 0.84
A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods (2009) 0.84
Models of RNA virus evolution and their roles in vaccine design. Immunome Res (2010) 0.83
Neurovirulence of type 1 polioviruses isolated from sewage in Japan. Appl Environ Microbiol (2002) 0.81
Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol J (2010) 0.80
A high throughput combinatorial library technique for identifying formalin-sensitive epitopes. J Immunol Methods (2006) 0.79
Estimating the risk of re-emergence after stopping polio vaccination. Front Microbiol (2012) 0.79
Inactivated polio vaccine: its proposed role in the final stages of polio eradication. Pan Afr Med J (2013) 0.75
Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines (2015) 0.75
Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol (2016) 0.75
Misconceptions about the new combination vaccine. BMJ (2004) 0.75
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (1979) 6.76
Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. J Virol (1973) 3.48
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.97
Summary of a workshop on new and useful methods in viral diagnosis. J Infect Dis (1978) 1.87
Rapid detection of human cytomegalovirus in the urine of humans. J Infect Dis (1985) 1.85
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.73
Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J (1989) 1.67
Ultrastructural study on the sequence of human cytomegalovirus infection in human diploid cells. Arch Gesamte Virusforsch (1973) 1.47
The prime-boost concept applied to HIV preventive vaccines. AIDS (1997) 1.20
Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis (2000) 1.16
Summary of a workshop on new and useful methods in rapid viral diagnosis. J Infect Dis (1984) 1.13
A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis (2001) 1.12
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses (1999) 1.05
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05
Prevention of diabetes in rats by bone marrow transplantation. Ann Surg (1981) 1.05
Characterization of multiple molecular interactions between human cytomegalovirus (HCMV) and human immunodeficiency virus type 1 (HIV-1). Virology (1990) 1.05
Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04
A rapid accurate procedure for the determination of serotonin in whole human blood. Biochem Med (1970) 1.00
Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses (1998) 0.99
Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr (1992) 0.99
Use of predictive markers of HIV disease progression in vaccine trials. Vaccine (2009) 0.99
Life-threatening complications of varicella. Am J Dis Child (1981) 0.98
Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J (1995) 0.97
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on new and useful techniques in rapid viral diagnosis. J Infect Dis (1980) 0.96
Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther (2001) 0.96
Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis (2000) 0.94
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine (1996) 0.93
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2012) 0.93
Progress in vaccine development for prevention of human cytomegalovirus infection. Curr Top Microbiol Immunol (1990) 0.93
Increased blood serotonin and platelets in early infantile autism. Arch Gen Psychiatry (1970) 0.92
Retracted Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration. J Virol (1992) 0.91
Human cytomegalovirus induces stage-specific embryonic antigen 1 in differentiating human teratocarcinoma cells and fibroblasts. J Exp Med (1989) 0.90
Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics (1999) 0.89
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J (2000) 0.85
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Synthesis of virus and macromolecules by rubella-infected cells. Nature (1966) 0.83
High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine (1991) 0.83
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83
Antiplatelet antibodies during the course of HIV-preventive vaccine trial. AIDS (1996) 0.81
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81
Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J (1997) 0.81
Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine (1999) 0.81
Maturational changes in blood serotonin levels and platelet counts. Biochem Med (1971) 0.81
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Can Dis Wkly Rep (1989) 0.80
Haemagglutinin of rubella virus. Nature (1967) 0.80
Evaluation of Abbott CMV-M enzyme immunoassay for detection of cytomegalovirus immunoglobulin M antibody. J Clin Microbiol (1988) 0.80
Neonatal mastitis due to Escherichia coli. J Pediatr (1970) 0.80
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J (1999) 0.80
Effects of L-dopa in autism. J Autism Child Schizophr (1972) 0.80
Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine (1990) 0.79
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine (1996) 0.79
Serologic survey of antibodies to cytomegalovirus in women and infants in Lima, Peru. J Infect Dis (1983) 0.79
Distribution of bacteria in the operating room environment and its relation to ventricular shunt infections: a prospective study. Childs Nerv Syst (1991) 0.78
[Quality evaluation of primary health care in an urban area of southern Brazil]. Rev Saude Publica (1994) 0.78
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med (1994) 0.77
Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Dev Biol Stand (1998) 0.77
Clinical development of a new inactivated hepatitis A vaccine. Infection (1997) 0.77
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis (1995) 0.77
Booster vaccination at 1 year with a rabies vaccine associated with DTP-IPV in infants living in a rabies endemic country. J Trop Pediatr (1999) 0.77
History of the acceptance of human diploid cell strains as substrates for human virus vaccine manufacture. Dev Biol Stand (1987) 0.76
Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr (1999) 0.76
Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med (1994) 0.76
Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis (1992) 0.76
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine (1997) 0.76
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J (1995) 0.76
Bridging the gap-a reply. J Theor Biol (2000) 0.75
Management of heel pain syndrome with acetic acid iontophoresis. J Am Podiatr Med Assoc (1999) 0.75
The anti-inflammatory action of locally injected ketorolac. J Am Podiatr Med Assoc (1998) 0.75
Effect of neonatal corticoid treatment on tryptophan and serotonin metabolism. Endocrinol Exp (1978) 0.75
Providing MMR vaccine to children. Minn Med (1991) 0.75
St. Thomas Immunization Initiative. A student-run community action project. J La State Med Soc (1997) 0.75
[Vaccination perspectives]. Sante (1994) 0.75
[Pediatric vaccines tomorrow]. Arch Pediatr (1996) 0.75
Reversible zidovudine-induced pure red cell aplasia. AIDS (1999) 0.75
Interesting case: an unusual case of oral ulceration. Br J Oral Maxillofac Surg (2005) 0.75
Formation of covalently closed cyclic dimers and catenanes of Escherichia coli phage lambda in the absence of known recombination systems. Virology (1976) 0.75
In utero fetal lower extremity examination by diagnostic ultrasound. J Am Podiatr Med Assoc (1988) 0.75
Case presentation of calcaneonavicular coalition in monozygotic twins. J Am Podiatr Med Assoc (1996) 0.75
Viral vaccine meeting held in Barcelona, October 25-28, 2003. Vaccine (2004) 0.75
Prevention of cytomegalovirus disease. Report of a conference. Pediatr Infect Dis (1984) 0.75
Standardization of BCG multiple puncture 40 mg and BCG live (intravesical) Theracys/BCG therapeutic Immucyst. Dev Biol Stand (1992) 0.75
DNA synthesis in chromatin preparations from human fibroblasts infected by cytomegalovirus. Arch Virol (1980) 0.75
Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J (1992) 0.75
Clinical comparison of preinjection anesthetics. J Am Podiatr Med Assoc (1998) 0.75
Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration. J Virol (1993) 0.75
Stability of BCG vaccine (intravesical) Theracys/BCG therapeutic ImmuCyst and its importance in clinical efficacy. Dev Biol Stand (1992) 0.75
Smokeless tobacco: a northern perspective. Can Nurse (1987) 0.75
[Research on human vaccine and its trends of application]. Zhonghua Yi Xue Za Zhi (1998) 0.75
First reported successful management of Serratia marcescens bacteremia after open heart surgery in a child. J Pediatr Surg (1975) 0.75
Multiple bioassays to assess the toxicity of a sanitary landfill leachate. Arch Environ Contam Toxicol (1984) 0.75
Postsynaptic adrenergic-cyclic AMP control of the serotonin content of cultured rat pineal glands. J Neurochem (1973) 0.75
The launch of an infant Haemophilus influenzae type B immunization programme in Iceland. Arctic Med Res (1991) 0.75